Idiopathic interstitial pneumonia medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 29: Line 29:


==Outline of Medical Therapy in Acute IIPs==
==Outline of Medical Therapy in Acute IIPs==
*The main treatment for acute interstitial pneumonia (AIP) is supportive care and corticosteroids.
Supportive care with Noninvasive or invasive mechanical ventilation is usually required, since most patients develop respiratory failure also the prevention of complications as venous thromboembolism, gastrointestinal bleeding and nosocomial pneumonia. The optimum dosing of glucocorticoids and its clinical benefit remains unclear, However these are widely used.
'''Glucocorticoids'''
*Once the diagnosis of AIP is made, high dose systemic glucocorticoids ( methylprednisolone 2 gm per day intravenously in divided doses) are given<ref>{{Cite journal  | last1 = Vourlekis | first1 = JS. | title = Acute interstitial pneumonia. | journal = Clin Chest Med | volume = 25 | issue = 4 | pages = 739-47, vii | month = Dec | year = 2004 | doi = 10.1016/j.ccm.2004.07.001 | PMID = 15564019 }}</ref> High dose glucocorticoid therapy are just supported by small case series with widely varying results <ref name="Olson-1990">{{Cite journal  | last1 = Olson | first1 = J. | last2 = Colby | first2 = TV. | last3 = Elliott| first3 = CG. | title = Hamman-Rich syndrome revisited. | journal = Mayo Clin Proc | volume = 65 | issue = 12 | pages = 1538-48 | month = Dec | year = 1990| doi =  | PMID = 2255216 }}</ref><ref name="Vourlekis-2000">{{Cite journal  | last1 = Vourlekis | first1 = JS. | last2 = Brown | first2 = KK. | last3 = Cool| first3 = CD. | last4 = Young | first4 = DA. | last5 = Cherniack | first5 = RM. | last6 = King | first6 = TE. | last7 = Schwarz | first7 = MI. | title = Acute interstitial pneumonitis. Case series and review of the literature. | journal = Medicine (Baltimore) | volume = 79 | issue = 6 | pages = 369-78 | month = Nov | year = 2000 | doi =  | PMID = 11144035 }}</ref><ref name="Suh-2006">{{Cite journal  | last1 = Suh | first1 = GY. | last2 = Kang | first2 = EH. |last3 = Chung | first3 = MP. | last4 = Lee | first4 = KS. | last5 = Han | first5 = J. | last6 = Kitaichi | first6 = M. | last7 = Kwon | first7 = OJ. | title = Early intervention can improve clinical outcome of acute interstitial pneumonia. | journal = Chest | volume = 129 | issue = 3 | pages = 753-61 | month = Mar | year = 2006 | doi = 10.1378/chest.129.3.753 | PMID = 16537878 }}</ref><ref name="Avnon-2009">{{Cite journal  | last1 = Avnon | first1 = LS. | last2 = Pikovsky | first2 = O. | last3 = Sion-Vardy | first3 = N. | last4 = Almog | first4 = Y. | title = Acute interstitial pneumonia-Hamman-Rich syndrome: clinical characteristics and diagnostic and therapeutic considerations. | journal = Anesth Analg | volume = 108 | issue = 1 | pages = 232-7 | month = Jan | year = 2009 | doi = 10.1213/ane.0b013e318188af7a | PMID = 19095855 }}</ref><ref name="Quefatieh-2003">{{Cite journal  | last1 = Quefatieh | first1 = A. | last2 = Stone | first2 = CH. | last3 = DiGiovine | first3 = B. | last4 = Toews | first4 = GB. | last5 = Hyzy | first5 = RC. | title = Low hospital mortality in patients with acute interstitial pneumonia. | journal = Chest | volume = 124 | issue = 2 | pages = 554-9 | month = Aug | year = 2003 | doi =  | PMID = 12907542 }}</ref'''>
'''Antibiotics'''
*Empiric broad-spectrum antibiotics are given to cover any infections.


==Outline of Medical Therapy in Chronic Fibrosing IIPs==
==Outline of Medical Therapy in Chronic Fibrosing IIPs==

Revision as of 14:43, 22 November 2013

Idiopathic Interstitial Pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Idiopathic interstitial pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

Endoscopy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Idiopathic interstitial pneumonia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Idiopathic interstitial pneumonia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onIdiopathic interstitial pneumonia medical therapy

CDC on Idiopathic interstitial pneumonia medical therapy

Idiopathic interstitial pneumonia medical therapyin the news

on Idiopathic interstitial pneumonia medical therapy

Directions to Hospitals Treating Idiopathic interstitial pneumonia

Risk calculators and risk factors for Idiopathic interstitial pneumonia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2];

Overview

As IIPs are heterogenous group of unknown interstitial lung disease with different natural history and clinical course, their management should be based on the clinical subtype. Optimal therapy for IPF is controversial as all currently available medications for IPF are severely limited by the lack of clear understanding of the natural history of IPF, the presence of various forms of study designs; heterogeneous patient groups, disputable diagnostic certainty; variable study duration; differences in medication formulation, dosage, route of administration, and duration of treatment; lack of placebo controls; variable intervals between evaluations and differing types of non quantitative assessment criteria. To date, most of treatment strategies have been based on eliminating or suppressing the inflammatory component. As no pharmacological therapy has been proven a clinical efficacy in altering or reversing the inflammatory process of IPF. The clinical trials over the past decades are hopefully held to clear the controversial dilemmas regarding which patients should be treated? When should therapy be started? What is the best treatment and how it should delivered and maintained? and how can be the treatment monitored especially that majority of patients are suffering comorbidities related functional limitations.

Medical Response of Clinical Subtype

The following points are a general summary for the responsiveness of each subtype of IIPs

Chronic Fibrosing IIPs

Idiopathic Pulmonary Fibrosis
  • poor response to corticosteroids and cytotoxic drugs
Idiopathic Nonspecific Interstitial Pneumonia
  • good response to corticosteroids

Acute/Subacute IIPs

Cryptogenic Organizing Pneumonia
  • good response to corticosteroids
Acute Interstitial Pneumonia (Hamman-Rich Syndrome)]
  • unknown response to corticosteroids

Smoking-related IIPs

Respiratory Bronchiolitis-Interstitial Lung Disease
  • good response to smoking cessation but unknown response to corticosteroids
Desquamative Interstitial Pneumonia
  • good response to smoking cessation but unknown response to corticosteroids

Outline of Medical Therapy in Acute IIPs

  • The main treatment for acute interstitial pneumonia (AIP) is supportive care and corticosteroids.

Supportive care with Noninvasive or invasive mechanical ventilation is usually required, since most patients develop respiratory failure also the prevention of complications as venous thromboembolism, gastrointestinal bleeding and nosocomial pneumonia. The optimum dosing of glucocorticoids and its clinical benefit remains unclear, However these are widely used. Glucocorticoids

  • Once the diagnosis of AIP is made, high dose systemic glucocorticoids ( methylprednisolone 2 gm per day intravenously in divided doses) are given[1] High dose glucocorticoid therapy are just supported by small case series with widely varying results [2][3][4][5][6]

References

  1. Vourlekis, JS. (2004). "Acute interstitial pneumonia". Clin Chest Med. 25 (4): 739–47, vii. doi:10.1016/j.ccm.2004.07.001. PMID 15564019. Unknown parameter |month= ignored (help)
  2. Olson, J.; Colby, TV.; Elliott, CG. (1990). "Hamman-Rich syndrome revisited". Mayo Clin Proc. 65 (12): 1538–48. PMID 2255216. Unknown parameter |month= ignored (help)
  3. Vourlekis, JS.; Brown, KK.; Cool, CD.; Young, DA.; Cherniack, RM.; King, TE.; Schwarz, MI. (2000). "Acute interstitial pneumonitis. Case series and review of the literature". Medicine (Baltimore). 79 (6): 369–78. PMID 11144035. Unknown parameter |month= ignored (help)
  4. Suh, GY.; Kang, EH.; Chung, MP.; Lee, KS.; Han, J.; Kitaichi, M.; Kwon, OJ. (2006). "Early intervention can improve clinical outcome of acute interstitial pneumonia". Chest. 129 (3): 753–61. doi:10.1378/chest.129.3.753. PMID 16537878. Unknown parameter |month= ignored (help)
  5. Avnon, LS.; Pikovsky, O.; Sion-Vardy, N.; Almog, Y. (2009). "Acute interstitial pneumonia-Hamman-Rich syndrome: clinical characteristics and diagnostic and therapeutic considerations". Anesth Analg. 108 (1): 232–7. doi:10.1213/ane.0b013e318188af7a. PMID 19095855. Unknown parameter |month= ignored (help)
  6. Walter, N.; Collard, HR.; King, TE. (2006). "Current perspectives on the treatment of idiopathic pulmonary fibrosis". Proc Am Thorac Soc. 3 (4): 330–8. doi:10.1513/pats.200602-016TK. PMID 16738197. Unknown parameter |month= ignored (help)

Template:WH Template:WS